Sugi Predict

Sugi Predict / Compounds / SCHEMBL477064

SCHEMBL477064

SCHEMBL477064

Clc1ccc2ncc(-c3ccncc3)n2n1

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.70
▸ DYRK2 Q92630 6/20 0.70
▸ CDK5 Q00535 5/20 0.70
▸ CDK5R1 Q15078 5/20 0.70
▸ DYRK1B Q9Y463 5/20 0.70
▸ DYRK3 O43781 4/20 0.70
▸ CCNA2 P20248 4/20 0.70
▸ CDK2 P24941 4/20 0.70
▸ FYN P06241 11/20 0.61
▸ CCNT1 O60563 3/20 0.61
▸ CDK9 P50750 3/20 0.61
▸ MKNK1 Q9BUB5 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15288602 0.85 DYRK1A (0.70) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL102252 0.85 DYRK1A (0.72) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL2948779 0.83 DYRK1A (0.68) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL23535568 0.83 DYRK1A (0.70) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL23535582 0.83 DYRK1A (1.00) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL28404217 0.82 DYRK1A (0.68) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL102796 0.82 DYRK1A (0.71) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL14765143 0.81 DYRK1A (1.00) DYRK1ADYRK2CDK5CDK5R1DYRK1B
SCHEMBL3033296 0.81 FYN (0.63) FYNMKNK1
SCHEMBL3033593 0.81 FYN (0.88) FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025336-A LIN28 inhibitors and methods of use thereof 加利福尼亚大学董事会 2025-05-23 — — CN disclosed
CN-115087657-B LIN28 inhibitors and methods of use thereof 加利福尼亚大学董事会 2025-01-21 — — CN disclosed
US-20230059009-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-02-23 — — US disclosed
US-20230059009-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-02-23 — — US disclosed
EP-4077332-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF The Regents of the University of California (US) 2022-10-26 — — EP disclosed
CN-115087657-A LIN28 inhibitor and method of use thereof 加利福尼亚大学董事会 2022-09-20 — — CN disclosed
WO-2021126779-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-24 — — WO disclosed
WO-2021126779-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-24 — — WO disclosed
US-9783543-B2 Aminoimidazopyridazines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-10 — — US disclosed
EP-2920176-B1 AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS Bayer Pharma AG (DE) 2017-09-13 — — EP disclosed
US-20150291599-A1 AMINOIMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-15 — — US disclosed
EP-2920176-A1 AMINOIMIDAZOPYRIDAZINES Bayer Pharma Aktiengesellschaft (DE) 2015-09-23 — — EP disclosed
WO-2014076162-A1 AMINOIMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-22 — — WO disclosed
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 — — EP disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 — — US disclosed
EP-2331546-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF Sanofi-aventis (FR) 2011-06-15 — — EP disclosed
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC (JP) 2010-08-26 — — US disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 — — WO disclosed
EP-1910369-A1 FUSED HETEROCYCLES AS LCK INHIBITORS Astellas Pharma Inc. (JP) 2008-04-16 — — EP disclosed
WO-2007013673-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF NR3C1, CNKSR1, NR3C2 DYRK1A 3666/4885DYRK2 3631/4885CDK5 842/4885
US-20230059009-A1 INHIBITORS OF LIN28 AND METHODS OF USE THEREOF LIN28A, DDX21, BMI1 DYRK1A 3932/4885DYRK2 3812/4885CDK5 402/4885
US-20150291599-A1 AMINOIMIDAZOPYRIDAZINES CCND2, CCND1, CCNI DYRK1A 1097/4885DYRK2 1363/4885CDK5 53/4885
US-20100216798-A1 FUSED HETEROCYCLES AS LCK INHIBITORS LCK, ZAP70, FYN DYRK1A 363/4885DYRK2 350/4885CDK5 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.